PTPRC and neoplasm: Furthermore, CD45+ tumor-infiltrating immune cells in TCh3 tumors clearly undergo more transcriptional changes upon anti-PD-L1 treatment that favor anti-tumor immunity; however, the underlying mechanisms for these observations remain unclear.